DexCom posts $1.31B quarter as Silvant Capital opens a $5.4M stake
What's the deal? Silvant Capital Management LLCDealroom has a profile for this one. Try Dealroom → bought a new stake in DexCom, Inc. (NASDAQ:DXCM) in the second quarter of 2026, purchasing 79,562 shares worth roughly $5,359,000, according to HoldingsChannel.com.
The numbers: DexCom reported quarterly revenue of $1.31 billion on July 30, 2026, up 13.1% year on year and ahead of the $1.29 billion consensus. The medical device maker posted earnings of $0.70 per share, topping analysts' estimate of $0.61 and well above the $0.48 it earned in the same period a year earlier.
What the company does: DexCom makes continuous glucose monitoring devices for people with diabetes. It carries a market cap of $34.05 billion, a return on equity of 35.94%, and a net margin of 20.12%.
Why now? The stock opened at $90.22 on August 21, 2026, near its 12-month high of $91.96 and far above the $54.11 low. Its 50-day moving average of $77.15 sits well above the 200-day figure of $70.79, signalling recent momentum.
Who else is buying? Smaller funds have also moved in. Wellington Grp LLCDealroom has a profile for this one. Try Dealroom → lifted its position 778.7% in the first quarter of 2026 to 536 shares, while Reflection Asset ManagementDealroom has a profile for this one. Try Dealroom →, Ascentis Independent AdvisorsDealroom has a profile for this one. Try Dealroom →, MCF Advisors LLCDealroom has a profile for this one. Try Dealroom →, and DV Equities LLCDealroom has a profile for this one. Try Dealroom → each opened new stakes. Institutional investors now own 97.75% of the company.
The other side: Insiders have been selling. EVP Jon Coleman sold 4,911 shares on June 4, 2026, at an average $74.13, and Director Mark G. Foletta sold 2,000 shares on August 3, 2026, at $85.32. Both trades ran under pre-arranged Rule 10b5-1 plans. Insiders sold 73,035 shares worth $5,446,673 during the second quarter of 2026.
Analyst view: Coverage remains positive. Deutsche BankDealroom has a profile for this one. Try Dealroom → started DexCom at "buy" with an $86.00 target, Truist FinancialDealroom has a profile for this one. Try Dealroom → set a $93.00 target with a "buy" rating, and CitigroupDealroom has a profile for this one. Try Dealroom → reiterated "buy" while raising its target to $88.00 from $84.00.
The signal: DexCom's beat and near-peak share price are drawing fresh institutional money even as executives trim holdings — a split that captures both confidence in the diabetes-tech market and caution about how much upside is left after the run.
Read more: Ticker Report
Image credit: booledozer
